Canada Spends Logo

Explore our Budget 2026 analysis

Grant: China-Canada Joint Health Research Initiative

Université Laval

$149,931.00

The therapeutic effect and safety of collagen binding vascular endothelial growth factor on myocardial infarction

FY 2009-10

Summary
Ischaemic Heart Disease is the most common cause of death in several countries around the world. Recent advances in the understanding of the mechanisms of neovascularization and the identification of potent angiogenic growth factors have led to the development of therapeutic angiogenesis for treatment of severe ischemic heart disease. Vascular endothelial growth factor (VEGF) is an important active protein for the induction of angiogenesis. Clinical trials of vascular endothelial growth factor (VEGF) therapy have proven that high dose of VEGF has beneficial effects on ischemic heart disease; however, potential problems associated with the prolonged and excessive production of VEGF remain a major concern. Our tremendous amount of work has been focused on improving cytokine therapy efficiency and decreasing associated side effects by increasing the local cytokine concentration in the injury sites. Here we propose to increase the local VEGF concentration in the infarction zone for achieving better therapeutic effect and lower VEGF diffusion risk in the circulation. As the main components of cardiac extracellular matrix (ECM) are type I and type III collagen, and about 85% of total collagen is type I, we propose to modify VEGF with a collagen-binding domain with gene engineering methods to enhance VEGF binding ability to cardiac collagen. The fused protein is expected to share the abilities of both angiogenesis and collagen binding. As pig coronary vascular system is more similar to that of human, the therapeutic effect for ischemic heart disease could be detected in the myocardial infarction model of pigs. By detecting the heart function, regional blood flow, scar size, capillary vessel number, VEGF diffusion in circulation, the therapeutic efficiency and safety would be analyzed. This work would be beneficial for developing a novel efficient and safe VEGF protein drug for ischemic heart disease therapy.
Program
China-Canada Joint Health Research Initiative
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
204131
Name
Zhang Ze
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
National Natural Science Foundation of China (Haidian, Beijing)
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
China-Canada Joint Health Research Initiative - Grants Program
Projecttitle
The therapeutic effect and safety of collagen binding vascular endothelial growth factor on myocardial infarction
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$149,931
Cihrequipment2
$0
Programname2
China-Canada Joint Health Research Initiative
Keyworddelim
Angiogenesis; Animal Experiment; Growth Factor Immobilization; Myocardial Infarction; Vascular Endothelial Growth Factor
Abstract
Ischaemic Heart Disease is the most common cause of death in several countries around the world. Recent advances in the understanding of the mechanisms of neovascularization and the identification of potent angiogenic growth factors have led to the development of therapeutic angiogenesis for treatment of severe ischemic heart disease. Vascular endothelial growth factor (VEGF) is an important active protein for the induction of angiogenesis. Clinical trials of vascular endothelial growth factor (VEGF) therapy have proven that high dose of VEGF has beneficial effects on ischemic heart disease; however, potential problems associated with the prolonged and excessive production of VEGF remain a major concern. Our tremendous amount of work has been focused on improving cytokine therapy efficiency and decreasing associated side effects by increasing the local cytokine concentration in the injury sites. Here we propose to increase the local VEGF concentration in the infarction zone for achieving better therapeutic effect and lower VEGF diffusion risk in the circulation. As the main components of cardiac extracellular matrix (ECM) are type I and type III collagen, and about 85% of total collagen is type I, we propose to modify VEGF with a collagen-binding domain with gene engineering methods to enhance VEGF binding ability to cardiac collagen. The fused protein is expected to share the abilities of both angiogenesis and collagen binding. As pig coronary vascular system is more similar to that of human, the therapeutic effect for ischemic heart disease could be detected in the myocardial infarction model of pigs. By detecting the heart function, regional blood flow, scar size, capillary vessel number, VEGF diffusion in circulation, the therapeutic efficiency and safety would be analyzed. This work would be beneficial for developing a novel efficient and safe VEGF protein drug for ischemic heart disease therapy.
Competitiondate
201003
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zhang, Ze; Dai, Jianwu
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Circ &Respiratory Hlth~ $149,931~ $0~
Université Laval - $149,931 Grant (2009-10) | Canada Spends